Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 4/20 | 0.74 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.74 |
| ▸ | PKM | P14618 | 3/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3138651 | 0.90 | CYP4F2 (0.60) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL23309172 | 0.85 | CYP4F2 (1.00) | CYP4F2CYP4A11PKMTHRBHTT | |
| Acetic Acid SCHEMBL10600414 | 0.84 | CYP4F2 (0.77) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL21703602 | 0.81 | CYP4F2 (0.63) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL5527697 | 0.79 | CYP4F2 (0.59) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL1173913 | 0.79 | CYP4F2 (0.50) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL29162182 | 0.78 | CYP4F2 (0.55) | CYP4F2CYP4A11PKMTHRBHTT | |
| Acetic Acid SCHEMBL2873953 | 0.77 | CYP4F2 (0.56) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL11421775 | 0.76 | CYP4F2 (0.55) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL958543 | 0.76 | CYP4F2 (0.55) | CYP4F2CYP4A11PKMTHRBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090835-A1 | Polymorphic forms of ziprasidone HCl and processes for their preparation | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS | 2008-04-17 | — | — | US | disclosed |
| US-20080091020-A1 | Polymorphic forms of ziprasidone HCI and processes for their preparation | TEVA PHARMACEUTICALS USA, INC. | 2008-04-17 | — | — | US | disclosed |
| US-20050043324-A1 | Polymorphic forms of ziprasidone HCI and processes for their preparation | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043324-A1 | Polymorphic forms of ziprasidone HCI and processes for their preparation | CRHBP, HAMP, HLA-DRB1 | CYP4F2 266/4885CYP4A11 305/4885PKM 1687/4885 |
| US-20080091020-A1 | Polymorphic forms of ziprasidone HCI and processes for their preparation | CRHBP, HAMP, HLA-DRB1 | CYP4F2 266/4885CYP4A11 305/4885PKM 1687/4885 |
| US-20080090835-A1 | Polymorphic forms of ziprasidone HCl and processes for their preparation | ADH1C, ADH1A, SLC39A3 | CYP4F2 169/4885CYP4A11 83/4885PKM 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.